Terconazole

DB00251

small molecule approved

Deskripsi

Terconazole is an anti-fungal drug that is mainly used to treat vaginal yeast infections (or vaginal candidiasis). It is classified as a triazole ketal derivative.^A178096 Terconazole was initially approved by the FDA in 1987.^{FDA label} This drug is available in cream and suppository forms and both have demonstrated high levels of safety, efficacy, and tolerability in clinical trials. ^A178093Due to the existence of 2 stereocentres, there are 4 possible stereoisomers for terconazole.

Struktur Molekul 2D

Berat 532.47

Wujud solid

Peta Jejaring Molekuler

Obat Target Gen Interaksi Enzim Transporter Carrier

Legenda: Obat • Target • Gen • Enzim • (Panah → menunjukkan arah efek / relasi) • Transporter • Carrier

1. Pendahuluan & Konsep

Fitur visualisasi ini dikembangkan menggunakan pendekatan Graph Theory untuk memetakan hubungan polifarmasi dan molekuler. Entitas (Obat, Target, Gen) direpresentasikan sebagai Simpul (Nodes), sedangkan hubungan biologisnya sebagai Sisi (Edges).

2. Sumber Data (Validasi)

Data Obat: Diekstraksi dari elemen drugbank-id dan name pada skema XML DrugBank.
Target Protein: Diambil dari elemen targets/target yang memuat polipeptida sasaran.
Genetik: Disinkronisasi dari sub-elemen gene-name dan varian snp-effects.
Genetik: Jumlah titik node dibatasi pada maksimal 10 (Slice=10) interaksi untuk menghindari tumpukan data.

3. Algoritma Visualisasi

Tata letak grafik menggunakan algoritma Force-Directed Graph (Barnes-Hut). Model fisika ini menerapkan gaya tolak-menolak antar simpul (Gravitasi: -3000) agar tidak tumpang tindih, serta gaya pegas (Spring: 0.04) pada garis penghubung untuk fleksibilitas interaksi.

4. Legenda Visual

Obat Utama (Pusat Analisis)

Target Protein (Mekanisme)

Gen (Faktor Genetik)

Metode ini mendukung analisis Precision Medicine dan evaluasi risiko Drug-Drug Interaction (DDI).

Profil Farmakokinetik

Waktu Paruh (Half-Life) 6.9 hours (range 4.0-11.3)

Volume Distribusi -

Klirens (Clearance) -

Absorpsi

Following intravaginal administration of terconazole in humans, absorption ranged from 5-8% in three hysterectomized subjects and 12-16% in two non-hysterectomized subjects with tubal ligations

Metabolisme

Systemically absorbed drug appears to be rapidly and extensively metabolized. Terconazole primarily undergoes oxidatative N- and O-dealkylation, dioxolane ring cleavage, and conjugation.

Rute Eliminasi

Following oral (30 mg) administration of 14C-labelled terconazole, excretion of radioactivity was both by renal (32-56%) and fecal (47-52%) routes.

Interaksi Obat

0 Data

Tidak ada data.

Target Protein

Lanosterol 14-alpha demethylase ERG11

Referensi & Sumber

Artikel (PubMed)

PMID: 2677365
Thomason JL: Clinical evaluation of terconazole. United states experience. J Reprod Med. 1989 Aug;34(8 Suppl):597-601.
PMID: 2696620
Pfaller MA, Gerarden T: Susceptibility of clinical isolates of Candida spp. to terconazole and other azole antifungal agents. Diagn Microbiol Infect Dis. 1989 Nov-Dec;12(6):467-71.

Link

FDA Approved Drug Products: TERAZOL (terconazole) cream and suppositories

Contoh Produk & Brand

Produk: 45 • International brands: 1

Produk

Taro-terconazole

Cream • 0.4 % • Vaginal • Canada • Generic • Approved
Terazol 3

Cream • 8 mg/1g • Vaginal • US • Approved
Terazol 3

Suppository • 80 mg/1 • Vaginal • US • Approved
Terazol 3

Cream • 8 mg/1g • Vaginal • US • Approved
Terazol 3

Cream • 8 mg/1g • Vaginal • US • Approved
Terazol 3

Suppository • 80 mg/1 • Vaginal • US • Approved
Terazol 3

Cream • 8 mg/1g • Vaginal • US • Approved
Terazol 3

Suppository • 80 mg/1 • Vaginal • US • Approved

Menampilkan 8 dari 45 produk.

International Brands

Terazol

Sekuens Gen/Protein (FASTA)

Sekuens dimuat saat dibutuhkan agar halaman tetap ringan.

Peringatan Keamanan